Collaboration Molecule definition

Collaboration Molecule means each of the [***] Molecule and the MGNX Option Molecule.
View Source
Collaboration Molecule means (a) MDV3100, (b) any Other Patented Molecule or (c) any metabolite, salt, hydrate, solvate, isomers, enantiomers, free acid form, free base form, crystalline form, pro-drug (including ester pro-drugs) form, racemate or optically active form of any compound described in clause (a) or (b).
View Source
Collaboration Molecule means: (a) Molecules owned or Controlled by Kineta as of the Effective Date or during the Option Period; and/or (b) Molecules that are conceived and reduced to practice, by or on behalf of a Party, or jointly by the Parties, as a direct result of such Party’s work under the Research Program.
View Source

Examples of Collaboration Molecule in a sentence

  • Neither Party nor any of its Affiliates shall, except as may be required by Applicable Law in the reasonable judgment of such Party or its Affiliates and its or their counsel, publicly disclose data or results of Clinical Trials or Nonclinical Studies that have not already been publicly disclosed with respect to any Collaboration Molecule or Product (whether conducted prior to or during the Term of this Agreement), except as provided in this Section 13.5.

  • Other representatives of each Party involved with the Collaboration Molecule, Lead Molecule or Licensed Product may attend meetings as non-voting participants, subject to the confidentiality provisions set forth in ARTICLE 10.

  • For clarity, JBI shall not have a license from Scholar Rock to Commercialize any Collaboration Molecule, Lead Molecule or Licensed Product unless and until JBI has exercised its License Option in accordance with Section 2.2 for Collaboration Molecules with such Pharmacological Profile.

  • For the avoidance of doubt and without limitation, both Parties shall have the right to propose to the JDC any studies of the MDV3100 Product not then part of a Joint Development Plan, or the expansion of development of the MDV3100 Product to include any new indication(s) within the Field, or the development of any Collaboration Molecule other than MDV3100.

  • On a Pharmacological Profile-by-Pharmacological Profile basis, Scholar Rock will notify the Program Committee upon designating that a Collaboration Molecule should be a Lead Molecule for such Pharmacological Profile based upon satisfaction of the Lead Criteria.

  • For the three (3) year period following expiration of the Exclusivity Period, Licensee will have a right of first negotiation (“RFN”) with respect to all molecules (other than Molecules) associated with any pain targets that are identified under the Research Program; provided Licensee may not exercise the RFN unless and until (i) Licensee exercises the Option and makes the Option Exercise Payment and (ii) Licensee had pursued or is pursuing the development of a Collaboration Molecule.

  • The following restrictions shall apply on a Pharmacological Profile-by-Pharmacological Profile basis with respect to any academic, scientific, medical or other publication or presentation or other disclosure by Scholar Rock or JBI that contains or refers to or otherwise relates to any Collaboration Molecule, Lead Molecule or Licensed Product prior to exercise of the License Option for such Pharmacological Profile.

  • For purposes of this Supplemental Agreement and the Collaboration Agreement, “Shared Program Activities” shall have the meaning set forth in the Collaboration Agreement, provided that activities with respect to a Collaboration Molecule or Product shall be understood to include activities with respect to a Product that consist of activities directed to the development or commercialization of (i) the CDx for use with the Product or (ii) the Product for use in conjunction with the CDx.

  • The Material Receiving Party shall not cause the Materials to be used by, delivered to or used for the benefit of any Third Party without the prior written consent of the Transferring Party; provided, that without limiting the foregoing, Company may not transfer or otherwise provide to any Third Party any Collaboration Molecule or Collaboration Product without obtaining the prior written consent of the JSC.

  • If Partner manufactures the Product itself (and thus there is no agreement to assign), then Partner shall supply such bulk Collaboration Molecule or finished Product, as applicable, to Medivation, for a reasonable period (not to exceed [*] after the effective date of termination), pursuant to a supply agreement to be negotiated in good faith by the Parties.


More Definitions of Collaboration Molecule

Collaboration Molecule means any therapeutic agent that (a) (i) binds to and modulates the activity of a Cardiomyopathy Target or (ii) expresses, in whole or in part, a Cardiomyopathy Target ((i) or (ii), “directed against” a Cardiomyopathy Target) and (b) (i) is Covered by a Fulcrum Patent Right that claims or discloses a method of using such therapeutic agent, (ii) with respect to which MyoKardia or any of its Affiliates or Licensees has initiated Lead Optimization within [**] after the Final Data Package Delivery Date or (iii) MyoKardia or any of its Affiliates or Licensees has in-licensed or acquired within [**] after the Final Data Package Delivery Date, (whether or not, in the case of clause (ii) or this clause (iii), Covered by a Fulcrum Patent Right); provided that [**] (collectively, the “Exceptions”) will not be deemed a Collaboration Molecule.
View Source
Collaboration Molecule means any therapeutic agent that is directed against or expresses, in whole or in part, a [**] Target; provided that any therapeutic agent created solely or jointly by Fulcrum, its Affiliates or Third Parties acting on its or their behalf outside the scope of the activities under this Agreement and without the use of any (i) Acceleron Technology, (ii) Confidential Information of Acceleron, (iii) Fulcrum Technology, (iv) Confidential Information of Fulcrum or (v) any other results or data, in the case of (iii), (iv) and (v), generated in the performance of or arising out of the Research Activities, will not be deemed a Collaboration Molecule.
View Source
Collaboration Molecule means (a) Dimebon; or (b) any Other Patented Molecule.
View Source
Collaboration Molecule means an agonist of the molecular target known as Stimulator of Interferon Genes (“STING”), which agonist is owned or Controlled by either Party at the Effective Date or by either or both Parties during the Term, [ * ].
View Source

Related to Collaboration Molecule

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid, a quantity of soluble lead compound exceeding, when calculated as lead monoxide, five per cent of the “dry weight” of the portion taken for analysis. In the case of paints and similar products and other mixtures containing oil or fat the “dry weight” means the dry weight of the material remaining after the substance has been thoroughly mixed and treated with suitable solvents to remove oil, fats, varnish or other media.

  • Licensed Compound means [***].

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.